International Psoriasis Council

Advancing Knowledge. Improving Care.

Benjamin Ehst Headshot

Benjamin

Ehst

,

MD, PhD

Investigator/Dermatologist
Oregon Medical Research Center
Portland
,
Oregon
,
United States
Councilor Since: September 8, 2022
IPC Councilor
Dr. Benjamin Ehst is a board-certified dermatologist with a doctorate in immunology who practices at the Broadway Medical Clinic in Portland, Oregon. He is also a clinical associate professor at Oregon Health and Science University (OHSU) and the co-owner/CMO and a lead investigator with Oregon Medical Research Center, where he has conducted over 100 clinical trials for various dermatologic devices and medications.
Dr. Ehst earned his undergraduate degree from the University of Chicago and his medical and doctoral degrees at the University of Minnesota. He completed residency training in dermatology at the Johns Hopkins Hospital in Baltimore, Maryland. He solidified his interest in medical practice and clinical research while studying the immune response to malaria at Hopkins’ Bloomberg School of Public Health.

Dr. Ehst spent his early career at OHSU as an Associate Professor in the Department of Dermatology and Director of Medical Dermatology. Alongside patient care and teaching, Dr. Ehst began his work in clinical research while at OHSU. Today, he enjoys a varied practice, seeing patients, teaching resident physicians, advising pharmaceutical companies, and running clinical trials. His special interests include inflammatory skin conditions like psoriasis and eczema, as well as skin-related issues in HIV-infected individuals.
Last Updated:
05/22/2025

Areas of Interest

Immunology behind the disease; therapeutic trial design; personalization of medicine; access to therapy around the world.

Languages Spoken

English

Involvement with Other Organization(s)

Member of the National Psoriasis Council.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026